Breaking News Instant updates and real-time market news.

TROV

Trovagene

$3.10

0.1 (3.33%)

08:05
11/28/16
11/28
08:05
11/28/16
08:05

Trovagene says PCM technology yields significantly greater detection sensitivity

Trovagene announced that the use of their Precision Cancer Monitoring technology for both urine and plasma EGFR mutation testing yielded significantly greater detection sensitivity than tissue testing alone. Data will be presented at the 17th World Conference on Lung Cancer, December 4-7 in Vienna, Austria. Trovagene's abstract entitled, A Highly Sensitive Next Generation Sequencing Platform for Detection of NSCLC EGFR T790M in Urine and Plasma, was selected for an oral presentation. This presentation will include data showing a 95% overall detection rate of EGFR T790M by combined urine and plasma versus 83% detection by tissue testing. Additionally, the detection rate in intrathoracic lung cancer disease, in the absence of distant metastases, was an unprecedented 93%. This data further validates the high sensitivity of Trovagene's, Trovera urine and blood liquid biopsy test to identify the EGFR T790M resistance mutation in patients with late-stage non-small cell lung cancer progressing on 1st or 2nd generation TKIs. Two additional abstracts, one a case series, focus on recent work demonstrating that EGFR ctDNA can serve as an early indicator of therapeutic response, providing valuable information particularly in the setting of late-stage patients treated with experimental therapeutics or in patients progressing on therapy. The dynamic changes in ctDNA EGFR systemic load observed in this case series is consistent with previous findings. A fourth poster presentation will feature cost of care analysis data demonstrating the value of a urine testing strategy as a dominant care pathway compared to a tissue testing strategy by saving costs and improving progression-free and overall survival for patients with non-small cell lung cancer.

  • 29

    Nov

TROV Trovagene
$3.10

0.1 (3.33%)

07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).
08/08/16
CANT
08/08/16
UPGRADE
CANT
Buy
Trovagene upgraded to Buy from Hold at Cantor
08/08/16
CANT
08/08/16
UPGRADE
Target $7
CANT
Buy
Trovagene upgraded to Buy with $7 target at Cantor
Cantor Fitzgerald analyst Bryan Brokmeier upgraded Trovagene to Buy from Hold citing the company's accelerating clinical business. In Q2, the company increased the number of physicians on the platform to approximately 700 physicians from 550 in Q1, Brokmeier tells investors in a research note. He points out that Trovagene is also targeting new biopharma collaborations. The analyst raised his price target for the shares to $7 from $5.
09/30/16
CANT
09/30/16
NO CHANGE
CANT
Trovagene outlook has improved, says Cantor
After meeting with Trovagene's management, Cantor analyst Bryan Brokmeier is more upbeat on the stock. He says that the company's new strategy :"significantly reduces" its cash needs, provides it with multiple potential positive catalysts and reduces its competition. The analyst keeps an $8 price target and Buy rating on the shares.

TODAY'S FREE FLY STORIES

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

San Francisco Federal…

MDR

McDermott

$7.13

0.3 (4.39%)

, MDSO

Medidata

$79.90

-0.35 (-0.44%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Hot Stocks
Breaking Hot Stocks news story on McDermott, Medidata »

McDermott to replace…

MDR

McDermott

$7.13

0.3 (4.39%)

MDSO

Medidata

$79.90

-0.35 (-0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

BASFY

BASF

$95.05

-0.18 (-0.19%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

BOBE

Bob Evans

$72.53

0.24 (0.33%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Bob Evans management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GLYC

GlycoMimetics

$13.41

1.31 (10.83%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

May Chicago Fed National…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

MDSO

Medidata

$79.90

-0.35 (-0.44%)

, PVTB

PrivateBancorp

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Hot Stocks
Medidata to replace PrivateBancorp in S&P 400 at open on 6/26 »

Canadian Imperial Bank of…

MDSO

Medidata

$79.90

-0.35 (-0.44%)

PVTB

PrivateBancorp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

MFG

Mizuho Financial Group

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Mizuho Financial Group management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

LULU

lululemon

$55.37

1.12 (2.06%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
lululemon management to meet with Barclays »

Meeting with CEO Laurent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AYR

Aircastle

$21.17

0.04 (0.19%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Aircastle management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

EXLS

ExlService

$55.05

0.15 (0.27%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
ExlService management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

NBIX

Neurocrine

$47.35

0.23 (0.49%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Neurocrine management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

GLYC

GlycoMimetics

$13.41

1.31 (10.83%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
GlycoMimetics management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

XOXO

XO Group

$17.60

0.1 (0.57%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
XO Group management to meet with B. Riley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Durable Goods Orders to be reported at 08:30 »

May Durable Goods Orders…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

June Dallas Fed Mfg…

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
JPMorgan life sciences analyst holds an analyst/industry conference call »

Life Science Tools and…

SAVE

Spirit Airlines

$52.55

0.02 (0.04%)

04:55
06/26/17
06/26
04:55
06/26/17
04:55
Conference/Events
Spirit Airlines management to meet with Raymond James »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

04:55
06/26/17
06/26
04:55
06/26/17
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

May Durable Goods Orders…

04:40
06/26/17
06/26
04:40
06/26/17
04:40
General news
FX Action: The yen is under the cosh »

FX Action: The yen is…

03:10
06/26/17
06/26
03:10
06/26/17
03:10
General news
FX Update: The dollar has traded steady-to-softer »

FX Update: The dollar has…

03:05
06/26/17
06/26
03:05
06/26/17
03:05
General news
FX Action: USD-CAD is softer today »

FX Action: USD-CAD is…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.